USPTO Examiner IVANOVA SVETLANA M - Art Unit 1627

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19293960SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONSAugust 2025February 2026Allow601NoNo
19274255TRICYCLIC DERIVATIVES AND RELATED USESJuly 2025January 2026Allow601YesNo
19237389PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIBJune 2025February 2026Abandon810NoNo
18960975HERBICIDAL AND PESTICIDAL COMPOSITIONS AND METHODS OF USE THEREOFNovember 2024October 2025Abandon1111NoNo
18901359PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIBSeptember 2024March 2025Allow510YesNo
18770514READY-TO-USE KETAMINE PREMIX FORMULATIONJuly 2024March 2025Allow821YesNo
18721770DRUG COMBINATION FOR TREATMENT OF GASTRIC CANCERJune 2024April 2025Allow1020NoNo
18740610METHODS RELATED TO OPIOID THERAPEUTICSJune 2024January 2025Allow700NoNo
18736166NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDSJune 2024September 2025Allow1510YesNo
186584601-(4-CARBONOIMIDOYLPHENOXY)-3-{4-[(E)-(PHENYLIMINO)METHYL]PHENOXY}PROPAN-2-OL AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)May 2024August 2024Allow400YesNo
18642074NOVEL THERAPYApril 2024July 2025Abandon1401NoNo
18635779CONTROLLED RELEASE FORMULATION AND MINIMALLY INVASIVE METHOD OF ADMINISTRATIONApril 2024July 2024Allow310NoNo
18629507HUMAN THERAPEUTIC AGENTSApril 2024June 2025Abandon1410NoNo
18624045(2E)-4-[(4-CHLOROPHENYL)AMINO]-N-PHENYL-2-(PHENYLIMINO)-1,3,5-DIOXAZEPINE-7-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)April 2024June 2024Allow200NoNo
184305271-(2-HYDROXYBENZYLIDENEAMINO)-5-PHENYLIMIDAZOLIDINE-2,4-DIONE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024April 2024Allow200NoNo
18428252METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITIONJanuary 2024January 2026Abandon2420NoNo
18423815COMBINATION THERAPYJanuary 2024September 2025Abandon2001NoNo
18418901FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITISJanuary 2024June 2025Allow1610YesNo
18417794COMPOSITIONS COMPRISING UROLITHIN COMPOUNDSJanuary 2024September 2025Abandon2020YesNo
18414316Prevention And Treatment Of Atrial Fibrillation/Flutter With Gamma-Ketoaldehyde ScavengersJanuary 2024May 2025Abandon1610NoNo
184042831-(4-CARBONOIMIDOYLPHENOXY)-3-{4-[(E)-(PHENYLIMINO)METHYL]PHENOXY}PROPAN-2-OL AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)January 2024April 2024Allow301YesNo
18397710(2E)-4-[(4-CHLOROPHENYL)AMINO]-N-PHENYL-2-(PHENYLIMINO)-1,3,5-DIOXAZEPINE-7-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)December 2023March 2024Allow201YesNo
18396955METHODS FOR ACUTE AND LONG-TERM TREATMENT OF OPIOID AND OPIOID-LIKE DRUG ADDICTIONDecember 2023October 2025Abandon2120NoNo
18521768METHODS AND COMPOSITIONS FOR REDUCING TOLERANCE TO OPIOID ANALGESICS USING IBOGAINE AND DERIVATIVES THEREOFNovember 2023May 2025Abandon1710NoNo
18518044MEDIUM CHAIN TRIGLYCERIDE COMPOSITIONSNovember 2023November 2024Allow1200YesNo
18492536BETULIN-CONTAINING BIRCH BARK EXTRACTS AND THEIR FORMULATIONOctober 2023December 2024Allow1400YesNo
18492750METHODS OF ADMINISTERING A PHARMACEUTICALLY ACCEPTABLE SALT OF 2-{[3,5-BIS(TRIFLUOROMETHYL)PHENYL]CARBAMOYL}-4-CHLOROPHENYL DIHYDROGEN PHOSPHATEOctober 2023August 2025Allow2210YesNo
184927131-(2-HYDROXYBENZYLIDENEAMINO)-5-PHENYLIMIDAZOLIDINE-2,4-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023February 2024Allow301YesNo
18479338PHARMACEUTICAL COMPOSITION CONTAINING PYRIDYLAMINOACETIC ACID COMPOUNDOctober 2023January 2026Allow2730NoYes
18374215METHOTREXATE FORMULATIONSeptember 2023February 2026Allow2830YesYes
18373838Methods and Compositions for Preventing and Treating Auditory DysfunctionsSeptember 2023February 2025Allow1710YesNo
18367560METHODS AND COMPOSITIONS FOR REDUCING TOLERANCE TO OPIOID ANALGESICS USING IBOGAINE AND DERIVATIVES THEREOFSeptember 2023April 2025Abandon1910NoNo
18466226SUSTAINED-RELEASE ANESTHETIC COMPOSITIONS AND METHODS OF PREPARATION THEREOFSeptember 2023December 2024Allow1500YesNo
18243572METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHYSeptember 2023March 2025Allow1901YesNo
18232599Ifetroban Treatment for Systemic SclerosisAugust 2023April 2025Abandon2010NoNo
18366414CONTROLLED RELEASE FORMULATION AND MINIMALLY INVASIVE METHOD OF ADMINISTRATION TO LOCALLY TREAT CANCERAugust 2023March 2024Allow711YesNo
18363961PYRIDYLAMINOACETIC ACID COMPOUND AND POLYOXYETHYLENE CASTOR OIL-CONTAINING PHARMACEUTICAL COMPOSITIONAugust 2023March 2026Allow3130YesYes
18353251COMPLEXES COMPRISING COLLAGEN PEPTIDES AND CURCUMINOIDS AND COMPOSITIONS THEREOFJuly 2023April 2025Allow2110YesNo
18221235METHODS FOR TREATING ATRIAL FIBRILLATIONSJuly 2023June 2025Abandon2440YesNo
18219783DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM)July 2023September 2024Allow1400YesNo
18196889PENETRATING TOPICAL PAIN RELIEF COMPOSITIONS AND METHODS OF USEMay 2023October 2023Allow510YesNo
18315954PHARMACEUTICAL COMBINATION COMPRISING A SELECTIVE S1P1 RECEPTOR AGONISTMay 2023May 2025Allow2411NoNo
18312857PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIBMay 2023August 2024Allow1620YesNo
18139916NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCEApril 2023March 2025Abandon2310NoNo
181358473-HYDROXYBUTYRATE ALONE OR IN COMBINATION FOR USE IN THE TREATMENT OF CRITICAL CARE TREATMENTApril 2023May 2025Allow2520YesNo
18135823METHODS OF TREATING HEPATIC ENCEPHALOPATHYApril 2023May 2024Abandon1320YesNo
18296290FORMULATIONS OF BENDAMUSTINEApril 2023March 2025Abandon2320NoYes
18296268FORMULATIONS OF BENDAMUSTINEApril 2023September 2025Abandon3030NoYes
18127612FORMULATIONS FOR TREATING CLUSTER SYMPTOMS ASSOCIATED WITH AUTISM SPECTRUM DISORDERMarch 2023July 2024Allow1610YesNo
18245583COMPOSITION FOR PROMOTING THE SKIN MICROBIOMEMarch 2023June 2025Allow2720YesNo
18117899METHODS OF TREATING HEPATIC ENCEPHALOPATHYMarch 2023July 2024Abandon1610NoNo
18108423PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIBFebruary 2023April 2023Allow200YesNo
18093940NON-HORMONAL COMPOSITIONS AND METHODS FOR MALE CONTRACEPTIONJanuary 2023February 2024Allow1300YesNo
18068263TREATMENT OF CANCER/INHIBITION OF METASTASISDecember 2022September 2025Allow3330NoNo
17926401PROPOFOL FOR DIAGNOSIS OF PRIMARY HEADACHENovember 2022December 2025Abandon3710YesNo
17971033MEROTERPENOID COMPOUNDS FOR USE IN THE PREVENTION AND TREATMENT OF A NEUROLOGICAL DISORDEROctober 2022December 2024Abandon2601NoNo
17959350Combination TherapyOctober 2022August 2024Allow2220YesYes
17955712COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADESeptember 2022September 2024Abandon2410NoNo
17934333METHOD AND COMPOSITIONS FOR THE TREATMENT OF ANEMIA THROUGH THE INHIBITION OF FURINSeptember 2022September 2024Allow2401YesNo
17913490N-PHENYL-3-MERCAPTOPROPANAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONSSeptember 2022January 2026Allow3910NoNo
17906389RENAL FUNCTION PROTECTIVE AGENTSeptember 2022November 2025Abandon3810NoNo
17940803GLYCINE RECEPTOR MODULATORS AND METHODS OF USESeptember 2022September 2024Allow2401NoNo
17908876NAPHTHOQUINONE-BASED CHALCONE DERIVATIVES AND USES THEREOFSeptember 2022February 2026Allow4101YesNo
17895946USE AND COMPOSITION FOR PROTECTION AGAINST ORGANOPHOSPHORUS POISONINGAugust 2022April 2025Allow3220YesNo
17894604COMPOUNDS, PHARMACEUTICAL FORMULATIONS, AND METHODS FOR TREATMENT OF CANCERAugust 2022August 2025Allow3610YesNo
17892948COMPOSITIONS AND METHODS FOR TREATMENT OF PLATINUM-BASED CHEMOTHERAPEUTIC RESISTANT TUMORSAugust 2022February 2026Allow4211YesNo
17821379TRPA1 ANTAGONIST FOR THE TREATMENT OF PAIN ASSOCIATED TO DIABETIC NEUROPATHIC PAINAugust 2022June 2024Abandon2210NoNo
17904587ANTI-RNA VIRUS DRUG AND APPLICATION THEREOFAugust 2022November 2025Abandon3901NoNo
17820553STEROL DERIVATIVES AND PREPARATION METHOD AND USES THEREOFAugust 2022February 2025Abandon3030NoNo
17887777INHIBITORS OF GLUCOCORTICOID RECEPTORAugust 2022December 2024Abandon2811NoNo
17884680COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDESAugust 2022August 2024Allow2420YesNo
17884918PENETRATING TOPICAL PAIN RELIEF COMPOSITIONS AND METHODS OF USEAugust 2022March 2024Allow1910YesNo
17884900PENETRATING TOPICAL PAIN RELIEF COMPOSITIONS AND METHODS OF USEAugust 2022April 2024Allow2020YesNo
17818667STEROL DERIVATIVES AND PREPARATION METHOD AND USES THEREOFAugust 2022September 2023Allow1300YesNo
17818302STEROL DERIVATIVES AND PREPARATION METHOD AND USES THEREOFAugust 2022September 2023Allow1300YesNo
17878984COMPOSITION FOR OPTIMIZED DIETARY SUPPLEMENT FORMULATIONSAugust 2022January 2024Abandon1701NoNo
17793998PESTICIDE COMPOSITIONS OF 1-PHENYL-TETRALIN DERIVATIVESJuly 2022November 2025Abandon4010NoNo
17758839STRESS MANAGEMENT IN HUMAN SUBJECTS IN NEED THEREOFJuly 2022December 2025Allow4120NoNo
17758749COMPOSITIONS FOR ALLEVIATING THE SYMPTOMS OF LOW ANTERIOR RESECTION SYNDROME BY TOPICAL ADMINISTRATION TO THE NEORECTUMJuly 2022October 2025Abandon4010NoNo
17792217TREATMENT OF PRIMARY BILIARY CHOLANGITIS WITH ELAFIBRANORJuly 2022November 2025Abandon4010NoNo
17811802USE OF SENICAPOC FOR TREATMENT OF NEUROPATHIC PAINJuly 2022February 2024Abandon1910NoNo
17856549PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USEJuly 2022November 2023Allow1710YesNo
17852252PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USEJune 2022October 2022Allow410YesNo
17852265PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USEJune 2022October 2022Allow400YesNo
17809196COMPOSITIONS, METHODS, SYSTEMS AND/OR KITS FOR PREVENTING AND/OR TREATING NEOPLASMSJune 2022May 2024Allow2310YesNo
17845961METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROMEJune 2022September 2024Allow2711YesNo
17842066Spironolactone Aqueous CompositionsJune 2022June 2023Abandon1220YesNo
17842102Spironolactone Aqueous CompositionsJune 2022June 2023Abandon1220YesNo
17841976CARBAMOYL PHENYLALANINOL ANALOGS AND USES THEREOFJune 2022October 2024Abandon2811NoNo
17838865COMPOUNDS FOR TREATING CUTANEOUS INFLAMMATION, FEMALE SEXUAL DISORDERS, AND IMPROVING SEXUAL FUNCTIONJune 2022August 2025Abandon3810NoNo
17784554IMPROVED STABILITY INSECTICIDAL COMPOSITIONS AND METHODS OF MAKING AND USING THE SAMEJune 2022December 2025Allow4210YesNo
17756978SOLID PHARMACEUTICAL PREPARATIONJune 2022September 2025Allow3910YesNo
17832838ANTIMICROBIAL COMPOSITIONS CONTAINING A SYNERGISTIC COMBINATION OF ACTIVATED CREATININE AND AN IMIDAZOLE ANTIFUNGAL AGENTJune 2022June 2024Allow2430YesNo
17830957Method and Compositions for Treating GlioblastomaJune 2022September 2025Abandon4011NoNo
17827079METHODS FOR ALLEVIATING KIDNEY DISEASE AND FIBROSIS OF ORGANMay 2022May 2024Allow2411NoNo
17756534COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF RESPIRATORY DISEASEMay 2022October 2025Abandon4101NoNo
17779787PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PULMONARY VASCULAR DISEASE AND/OR CARDIAC DYSFUNCTION IN FONTAN-PALLIATED PATIENTSMay 2022November 2025Abandon4210NoNo
17756437Z-STILBENE AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOFMay 2022June 2025Abandon3601NoNo
17746458METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSISMay 2022January 2026Abandon4451NoNo
17755993Prooxidative chain-transfer agents for use in the treatment of malignant tumour or infectious diseasesMay 2022March 2026Abandon4611YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner IVANOVA, SVETLANA M.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
21
Examiner Affirmed
14
(66.7%)
Examiner Reversed
7
(33.3%)
Reversal Percentile
49.1%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
102
Allowed After Appeal Filing
15
(14.7%)
Not Allowed After Appeal Filing
87
(85.3%)
Filing Benefit Percentile
17.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 14.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner IVANOVA, SVETLANA M - Prosecution Strategy Guide

Executive Summary

Examiner IVANOVA, SVETLANA M works in Art Unit 1627 and has examined 904 patent applications in our dataset. With an allowance rate of 50.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.

Allowance Patterns

Examiner IVANOVA, SVETLANA M's allowance rate of 50.2% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by IVANOVA, SVETLANA M receive 1.74 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by IVANOVA, SVETLANA M is 28 months. This places the examiner in the 67% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +57.7% benefit to allowance rate for applications examined by IVANOVA, SVETLANA M. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 19.8% of applications are subsequently allowed. This success rate is in the 21% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 25.1% of cases where such amendments are filed. This entry rate is in the 35% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 34.8% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 34% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 58.0% of appeals filed. This is in the 32% percentile among all examiners. Of these withdrawals, 48.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 60.7% are granted (fully or in part). This grant rate is in the 65% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 56% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.